Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 3/20 | 0.34 |
| ▸ | FGF2 | P09038 | 3/20 | 0.34 |
| ▸ | VEGFA | P15692 | 3/20 | 0.34 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15508127 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL17300175 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL18733215 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL15508089 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL18030218 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL18333048 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL17300176 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL18733408 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL12819629 | 1.00 | MAPK1 (0.44) | MAPK1GJB2LGALS8LGALS3LGALS4 | |
| SCHEMBL9547050 | 0.93 | MAPK1 (0.51) | MAPK1GJB2LGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014165107-A2 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274930-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TLR5, TLR1, MANBA | MAPK1 515/4885GJB2 4739/4885LGALS8 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.